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D– red blood cells (RBCs), always in short supply, and Rh 
immune globulin (RhIG) are not needed for patient care if D+ 
RBCs can safely be transfused. According to a recent work group 
recommendation, patients with the RHD*weak D type 4.0 allele 
can be considered D+. We report an African American woman 
who presented for delivery at the end of the third trimester, 
at which time anti-U and a serologic weak D phenotype were 
recognized, requiring U–, D– RBC units. We obtained 3 U– RBC 
units, including 1 D– unit. Later, the RHD*weak D type 4.0 allele 
was determined by RHD genotyping, only 6 days before delivery. 
The patient had an uneventful vaginal delivery of a D+ baby. 
No transfusion was needed for mother or baby. In this case, a 
pregnant woman with the RHD*weak D type 4.0 allele can safely 
be managed as D+, relaxing the unnecessary D– restriction for 
the limited U– RBC supply. The procured U–, D– RBC unit was 
frozen with 14 days of shelf-life remaining. To conserve D– RBC 
units, not limited to U–, for patients with a definite need, we 
recommend molecular analysis of a serologic weak D phenotype 
before a transfusion becomes imminent. The best time to resolve 
a serologic weak D phenotype with RHD genotyping is early in a 
pregnancy. Immunohematology 2021;37:1–4.
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Hemolytic disease of the fetus and newborn is reliably 
prevented by proper management, based on antenatal D 
typing and screening for red blood cell (RBC) antibodies. Many 
hospital laboratories do not determine the RHD genotype 
of pregnant women with a serologic weak D phenotype, 
because these women are often managed as D–.1 However, 
Rh immune globulin (RhIG) and provision of D– RBC 
units are unnecessary if D+ RBCs can safely be transfused. 
An Interorganizational Work Group on RHD Genotyping 
recommended in 20152 to phase-in RHD genotyping for 
patients with a serologic weak D phenotype. The same 
authors3 specified their recommendation in 2020 to phase-out 
the reporting of a “serologic weak D phenotype” and resolve all 
weak D types with RHD genotyping.
We report a pregnant woman with anti-U and a serologic 
weak D phenotype. The clinical workup in this case illustrated 
the importance of molecular analysis of serologic weak D 
phenotypes early in the pregnancy to preserve rare D– RBC 
units and to eliminate the unnecessary administration of 
RhIG.
Case Report and Results
A 23-year-old African American woman (gravida 2, para 
1) presented for childbirth. The woman had no history of blood 
transfusion. Testing of her blood sample showed her RBCs to 
be group B with a serologic weak D phenotype; anti-U was 
identified by the antibody screening process (Table 1). Without 
any molecular information for her RHD genotype, the woman 
was initially considered to be managed as D–. We decided to 
obtain 3 U– RBC units; however, only 1 was D–.
In the week before delivery, nucleotide sequencing of the 
RHD gene was performed on the mother and, later, on the 
neonate.4 Based on the three amino acid substitutions (Table 
2), we concluded that the mother carried the RHD*weak D 
type 4.0 allele (Table 2) and was hemizygous for the RHD gene. 
The neonate was a compound heterozygote for the RHD gene 
with a RHD*weak D type 4.0 allele from the mother in trans 
to a normal RHD allele from the father. A total of 12 and 13 
nucleotide changes were confirmed in the mother and neonate, 
respectively (Table 2).
Zygosity testing for the RHD gene was done by a 
quantitative fluorescence–polymerase chain reaction (QF-
PCR) assay.5 The mother was hemizygous (one copy) and the 
neonate was homozygous (two copies) for the RHD gene. The 
QF-PCR is the preferred method for RHD zygosity testing in 
individuals of African descent, although it is known to have 
limitations in white individuals where a restriction fragment–
length polymorphism (RFLP) assay may be the more reliable 
method.6–8
We still applied an RFLP assay that is designed to detect 
the standard downstream Rhesus box, indicative of the 
presence of an RHD gene (i.e., lack of the RHD deletion).7 
However, the mother who carried an RHD gene tested negative 
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(seemingly no copies) in this RFLP assay, and the neonate who 
carried two copies of the RHD gene tested hemizygous for the 
RHD gene (seemingly only one copy). These discrepancies 
are explained by variations in the downstream Rhesus box of 
individuals of African ancestry and are a known limitation of 
the RFLP assay in these individuals.6,8,9
The mother, with an unexplained hemoglobin (Hb) 
concentration of 9.8 g/dL prepartum, had an uneventful 
vaginal delivery. Her Hb dropped by 0.9 g/dL, and she did 
not require transfusion (Table 1). The neonate’s blood sample 
typed as group B, D+ with normal clinical laboratory results 
(Table 1), and no treatment was required. The 2 U–, D+ RBC 
units were returned and used in the care of another pregnant 
woman with anti-U. The unnecessarily procured U–, D– RBC 
unit had to be frozen, however, with only 14 days of shelf-life 
remaining.
Discussion
The present clinical report exemplifies the advantage 
of RHD genotyping in expectant mothers to identify RHD 
alleles that allow the mothers to be safely treated as D+.3 The 
molecular analysis should be performed early in a pregnancy. 
This approach, which was missed at the first-time maternity 
visit in our patient, would have allowed for an efficient 
organization of RBC genotyping with or without antibody 
identification. Most hospitals would typically send samples 
to an immunohematology reference laboratory. In our case, 
while birth was imminent, the shipping and testing was 
accomplished within 5 days, including a weekend. The extra 
cost inflicted by this time constraint could surely have been 
avoided with better planning of the required tests during 
the pregnancy. Complex serologic and molecular testing in 
immunohematology are more prone to errors when performed 
under extreme time constraints and thus should be avoided.
The blood supply in transfusion service is often limited, 
especially for patients with the D– phenotype, and more so if 
antibodies to high-prevalence RBC antigens are also present.10 
For the expectant mother in our study, a compatible donor 
with a U–, D– phenotype is extremely rare, representing <0.1 
percent of the African American population.11 U–, D+ RBC 
units are also very rare, but there are five to ten times more 
donors if the D– restriction can be removed.
Supporting every patient who is D+ due to RHD*weak 
D type 4.0 with D– RBC units to prevent anti-D would be 
a burden and is discouraged.3,12 D– RBC transfusion and 
RhIG administration may be considered during pregnancy 
in an abundance of caution, although several health care 
systems are considering moving to an exclusively D+ 
transfusion management policy.3,13,14 Pregnant women with 
the RHD*weak D type 4.0 allele, who were never shown to 
produce an alloanti-D with adverse clinical outcome, could 
falsely be diagnosed of carrying an alloanti-D that is actually 
Table 1. Clinical laboratory results for mother and neonate























RHD allele RHD*weak D type 4.0 and normal RHD
RHD zygosity Compound heterozygous
Hematology
Hemoglobin, g/dL 17.6 (14.0–24.0)
Unconjugated bilirubin,  
mg/dL
At birth 4.9 (<6)
4 hours after birth 5.5 (<6)
Reticulocyte count, % 4.46 (3.0–7.0)
†At the end of the third trimester.
‡ Tested by the conventional tube method at immediate spin (Anti-D Blend, 
oligoclonal antibody mixture with clone numbers BS232, BS221, and H41 
11B7; Bio-Rad, Hercules, CA).
§At birth.
DAT = direct antiglobulin test.
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due to RhIG administration.13,14 This passively acquired anti-D 
can mislead the results of compatibility testing, when RBC 
units are crossmatched in preparation for delivery. Pitfalls 
of mistaking passive anti-D for active immunization can be 
avoided by obtaining a history and performing an anti-D 
titer.15 In summary, we decided to treat the current patient as 
D+ for transfusion purposes and recommended against RhIG 
administration during pregnancy and after the birth of the D+ 
baby boy.
Studies on cost and financial implications explored the 
economic aspect of RHD genotyping for pregnant women with 
a weak D phenotype.16,17 If the personal health information 
is properly maintained and shared, particularly in highly 
developed countries like the United States, RHD genotyping 
would add only a one-time testing cost for each pregnant 
woman with a weak D phenotype, while providing a rationale 
for the transfusion strategy during the rest of a woman’s 
life.18 This strategy could prevent unnecessary costs and risks 
associated with RhIG administration and follow-up scheduling 
during the current and every subsequent pregnancy.3 The 
best time to resolve a serologic weak D phenotype with RHD 
genotyping is early in the first pregnancy.2
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